US2011150926A1PendingUtilityA1

Influenza vaccines

62
Assignee: ALSHARIFI MOHAMMEDPriority: Aug 1, 2008Filed: Jul 31, 2009Published: Jun 23, 2011
Est. expiryAug 1, 2028(~1.9 yrs left)· nominal 20-yr term from priority
Inventors:Mohammed AlsharifiArno Mullbacher
A61K 2039/58A61K 39/145A61K 2039/5252C12N 2760/16234A61K 39/12C12N 2760/16134A61K 2039/70C12N 2760/16161A61K 2039/545A61K 2039/543C12N 7/00A61P 37/04C12N 2760/16163A61P 31/16C12N 2760/16171C07K 16/108
62
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The invention relates to a method for the treatment or prevention of an influenza virus infection in a subject, the method comprising administering to the subject a therapeutically effective amount of a gamma-irradiated influenza virus.

Claims

exact text as granted — not AI-modified
1 . A method for the treatment or prevention of infection by multiple influenza virus subtypes in a subject, the method comprising intranasally administering to the subject a therapeutically effective amount of a gamma-irradiated influenza virus. 
     
     
         2 . A method for inducing or enhancing cross-reactive immunity against multiple influenza virus subtypes in a subject, the method comprising intranasally administering to the subject a therapeutically effective amount of a gamma-irradiated influenza virus. 
     
     
         3 . The method according to  claim 2 , wherein said cross-reactive immunity comprises cross-reactive cellular immunity and cross-reactive humoral immunity. 
     
     
         4 . The method according to  claim 3 , wherein said cross-reactive cellular immunity comprises either or both of:
 (i) a cross-reactive helper T cell response   (ii) a cross-reactive cytotoxic T cell response.   
     
     
         5 . The method according to  claim 1 , wherein said gamma-irradiated influenza virus is prepared from a virus stock purified by tangential/cross-flow filtration. 
     
     
         6 . The method according to  claim 1 , wherein said gamma-irradiated influenza virus is generated by gamma-irradiating a frozen viral preparation. 
     
     
         7 . The method according to  claim 1 , wherein said gamma-irradiated influenza virus is prepared in a freeze-dried form. 
     
     
         8 . The method according to  claim 1 , wherein said multiple influenza virus subtypes comprise one or more of human, avian, swine, canine or equine influenza virus subtypes. 
     
     
         9 . The method according to  claim 1 , wherein said multiple influenza virus subtypes comprise influenza A subtype HPAI A(H5N1). 
     
     
         10 . The method according to  claim 1 , wherein said multiple influenza virus subtypes comprise influenza A subtype H1N1 09 Swine Flu. 
     
     
         11 . The method according to  claim 1 , wherein said gamma-irradiated influenza virus is selected from the group consisting of A/WSN [H1N1], A/PR8 [H1N1], A/JAP [H2N2] and A/PC [H3N2]. 
     
     
         12 . The method according to  claim 1 , wherein said gamma-irradiated influenza virus is generated by exposing said virus to a total dose of between about 6.5×10 4  rad and about 2×10 7  rad of gamma rays. 
     
     
         13 . The method according to  claim 1 , wherein said gamma-irradiated influenza virus is generated by exposing said virus to a total dose of about 1×10 6  rad of gamma rays. 
     
     
         14 . A method of producing an intranasal influenza vaccine capable of inducing cross-reactive immunity against multiple influenza virus subtypes, the method comprising inactivating a preparation of influenza virus by gamma-irradiation. 
     
     
         15 . The method according to  claim 14 , wherein said preparation of influenza virus is purified by tangential/cross-flow filtration prior to said inactivating by gamma-irradiation. 
     
     
         16 . The method according to  claim 14 , wherein said preparation of influenza virus is gamma-irradiated while frozen. 
     
     
         17 . The method according to  claim 14 , comprising an additional step of freeze-drying said virus after said inactivating by gamma-irradiation. 
     
     
         18 . The method according to  claim 14 , wherein said multiple influenza virus subtypes comprise influenza A subtype HPAI A(H5N1) or influenza A subtype H1N1 09 Swine Flu. 
     
     
         19 . (canceled) 
     
     
         20 . The method according to  claim 14 , wherein said inactivating comprises exposing said virus to a total dose of between about 6.5×10 4  rad and about 2×10 7  rad of gamma rays. 
     
     
         21 . The method according to  claim 14 , wherein said inactivating comprises exposing said virus to a total dose of about 1×10 6  rad of gamma rays. 
     
     
         22 . (canceled) 
     
     
         23 . (canceled) 
     
     
         24 . (canceled) 
     
     
         25 . (canceled) 
     
     
         26 . (canceled)

Join the waitlist — get patent alerts

Track US2011150926A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.